2 completed, 2 unknown, 1 active not recruiting. 3 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Unknown 2, Active not recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Beijing Health Guard Biotechnology, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine Nonavalent HPV study vaccine, GARDASIL® 9 - Human Papillomavirus Infection | Phase 3 | Unknown | Beijing Health Guard Biotechnology, Inc | 1260 | 2023-11-21 | 2024-01-23 |
| A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9 - Human Papillomavirus Infection | Phase 3 | Active not recruiting | Beijing Health Guard Biotechnology, Inc | 2750 | 2022-03-23 | 2022-12-27 |
| A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®） - Human Papillomavirus Infection | Phase 3 | Unknown | Beijing Health Guard Biotechnology, Inc | 12000 | 2020-12-05 | 2023-01-04 |
| A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae) - Human Papilloma Virus Infection | Phase 2 | Completed | Beijing Health Guard Biotechnology, Inc | 780 | 2020-05-23 | 2023-01-23 |
| A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine - Human Papillomavirus Infection | Phase 1 | Completed | Beijing Health Guard Biotechnology, Inc | 160 | 2019-09-01 | 2023-01-17 |
Papillomavirus Infections (5) · Anus Neoplasms (3) · Condylomata Acuminata (3) · Uterine Cervical Neoplasms (3) · Vulvar Neoplasms (3) · Vaginal Neoplasms (2)
Papillomavirus Vaccines (5) · Vaccines (5)
China (4) · Indonesia (1)
Yongjiang Liu, Bachelor (4) · Yu Hongyang (1)